Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in patients with advan...

Detaylı Bibliyografya
Asıl Yazarlar:	Leijen, S, Middleton, MR, Tresca, P, Kraeber-Bodéré, F, Dieras, V, Scheulen, M, Gupta, A, Lopez-Valverde, V, Xu, Z, Rueger, R, Tessier, J, Shochat, E, Blotner, S, Naegelen, V, Schellens, J, Eberhardt, W
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2012

Benzer Materyaller

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
Yazar:: Kraeber-Bodéré, F, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Yazar:: Leijen, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Yazar:: Leijen, S, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
Yazar:: Julia Koch-Heier, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S
Yazar:: Michel Theron, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Challenges in nuclear medicine: innovative theranostic tools for personalized medicine
Yazar:: Françoise eKraeber-Bodéré, ve diğerleri
Baskı/Yayın Bilgisi: (2014-07-01)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
Yazar:: Joseph F. Grippo, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
Yazar:: Clément Bailly, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
Yazar:: Yan Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
Yazar:: Makoto Wada, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
Yazar:: Appels, N, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
Yazar:: Jia‐yu Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2
Yazar:: Martin Bauer, ve diğerleri
Baskı/Yayın Bilgisi: (2024-02-01)

Fire Risk Model for Fires in Ro-Ro Ship Ro-Ro Spaces
Yazar:: Sixten Dahlbom, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Yazar:: Karthik Ramasamy, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

NOP Receptor Agonist Ro 64-6198 Decreases Escalation of Cocaine Self-Administration in Rats Genetically Selected for Alcohol Preference
Yazar:: Hongwu Li, ve diğerleri
Baskı/Yayın Bilgisi: (2019-03-01)

Mek1 and Mek2 Functional Redundancy in Erythropoiesis
Yazar:: Laurent Beuret, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Ro-ro ships and shipping /
Yazar:: Grey, Michael
Baskı/Yayın Bilgisi: (1985)

Vehicles on ro/ro ships
Yazar:: 8096 British Standards Institution, ve diğerleri

Mek mulung
Yazar:: Malaysia. Kementerian Perpaduan, Kebudayaan, Kesenian dan Warisan. Jabatan Muzium dan Antikuiti, ve diğerleri
Baskı/Yayın Bilgisi: ([dat)

Mek mulung
Yazar:: Malaysia. Kementerian Kebudayaan, Belia dan Sukan. Bahagian Kebudayaan
Baskı/Yayın Bilgisi: (1981)

MEK Inhibition
Yazar:: Emilien Loeuillard, PhD, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)

Ro/ro ships (1978-1978)
Yazar:: British Ship Research Association
Baskı/Yayın Bilgisi: ([19-)

Some elements of the ro-ro terminals
Yazar:: R. Maksimavičius
Baskı/Yayın Bilgisi: (2004-04-01)

Safety, Pharmacokinetics/Pharmacodynamics, and Absolute Bioavailability of Dexmedetomidine Hydrochloride Nasal Spray in Healthy Subjects: A Randomized, Parallel, Escalating Dose Study
Yazar:: Yun Kuang, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Cell Tracking in Cancer Immunotherapy
Yazar:: Justine Perrin, ve diğerleri
Baskı/Yayın Bilgisi: (2020-02-01)

Real de-escalation or escalation in disguise?
Yazar:: Maggie Banys-Paluchowski, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

AN ANALYSIS OF THE ITALIAN RO-RO AND RO-PAX NETWORK IN THE YEARS 2008-2015
Yazar:: Marino LUPI, ve diğerleri
Baskı/Yayın Bilgisi: (2017-12-01)

Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice
Yazar:: R. L. Shamraev, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

Some features of roAp stars spectrum
Yazar:: A. V. Shavrina, ve diğerleri
Baskı/Yayın Bilgisi: (2017-03-01)

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
Yazar:: Xuan Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Unveiling the Ro60-Ro52 complex
Yazar:: Laura R. Rodríguez, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

»Ci-ce-ro! Ci-ce-ro!«
Yazar:: Marie Theres Fögen
Baskı/Yayın Bilgisi: (2007-01-01)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
Yazar:: Marc A. Simon, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

[18F]-Fludarabine for Hematological Malignancies
Yazar:: Louisa Barré, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Yazar:: Pacey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

The Pharmacodynamics of Antipsychotic Drugs in Women and Men
Yazar:: Mary V. Seeman
Baskı/Yayın Bilgisi: (2021-04-01)

Assessment of lymph nodes and prostate status using early dynamic curves with 18F-choline PET/CT in prostate cancer
Yazar:: Cédric eMathieu, ve diğerleri
Baskı/Yayın Bilgisi: (2015-09-01)

Focus on the controversial aspects of 64Cu-ATSM in tumoral hypoxia mapping by PET imaging
Yazar:: Mathilde eColombié, ve diğerleri
Baskı/Yayın Bilgisi: (2015-08-01)

Interest of Pet Imaging in Multiple Myeloma
Yazar:: Bastien Jamet, ve diğerleri
Baskı/Yayın Bilgisi: (2019-04-01)